<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184533</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-30587</org_study_id>
    <secondary_id>NCI-2014-01361</secondary_id>
    <secondary_id>PROS0047</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02184533</nct_id>
  </id_info>
  <brief_title>Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Knox</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite&#xD;
      when administered in combination with radiation therapy to subjects with metastatic cancer&#xD;
      based on safety and tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of sodium selenite when given in&#xD;
           combination with palliative radiation therapy&#xD;
&#xD;
        -  To assess the safety and tolerability of the combination of sodium selenite and&#xD;
           palliative radiation therapy in metastatic cancer&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the pharmacokinetics of sodium selenite&#xD;
&#xD;
        -  To evaluate the anti tumor activity of sodium selenite and palliative radiation therapy&#xD;
           when given in combination&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive sodium selenite orally (PO) 2 hours before daily radiation therapy&#xD;
      treatments. Treatment continues for the duration of the course of radiation therapy in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the maximum dose at which =&lt; 1 of 3 to 6 subjects in a dose group experience a drug-related dose-limiting toxicity, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (v)4.0</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of the combination using the NCI Common Toxicity Criteria v4.0 grading system for adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Safety observations and measurements including adverse events, laboratory data, vital signs, and performance status will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile</measure>
    <time_frame>Week 1, day 1: at predose; 15 minutes; and at 1, 2, 4, and 24 hours; weeks 2 and 4, day 1: at predose and 1 hour</time_frame>
    <description>PK parameters will be calculated using non-compartmental and/or compartmental models and PK parameters (if possible, maximum concentration [Cmax], time to Cmax, area under the curve during the dosing interval, half-life, oral clearance) will be summarized and presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall biochemical response rate</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>Biochemical response defined as PSA decline &gt;= 50% from baseline at 8 weeks of therapy and which has been confirmed with a second PSA at &gt;= 3 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor responses within the radiation therapy field, assessed using Response Evaluation Criteria in Solid Tumors 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (complete response, partial response and stable disease) within the radiation therapy field</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasmacytoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium selenite</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (sodium selenite and radiation therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy or&#xD;
             prostatectomy specimen (primary site), or histological confirmation of adenocarcinoma&#xD;
             /carcinoma in a metastatic site of disease in the setting of elevated PSA and imaging&#xD;
             consistent with metastatic prostate cancer, or history of prostate cancer with&#xD;
             documented metastasis, or histologically confirmed other solid tumor malignancy,&#xD;
             multiple myeloma, or plasmacytoma with pathological confirmation of metastasis&#xD;
&#xD;
          2. Metastatic cancer requiring palliative radiation therapy&#xD;
&#xD;
          3. For patients with metastatic prostate cancer, PSA ≥ 2 ng/mL, except for patients who&#xD;
             have recently started androgen deprivation therapy with PSA &lt; 2 ng/mL&#xD;
&#xD;
          4. Age ≥18 years&#xD;
&#xD;
          5. Life expectancy greater than 3 months&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or Karnofsky&#xD;
             performance status ≥ 80%&#xD;
&#xD;
          7. QT interval corrected using Fridericia's method (QTcF) &lt; 460 msec (see Appendix C for&#xD;
             Fredericia's criteria).&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Inadequate organ function, as evidenced by any of the following at screening:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1500/µL&#xD;
&#xD;
               -  Platelet count ≤ 100 x 109/L&#xD;
&#xD;
               -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST, and/or ALT &gt; 2 x ULN&#xD;
&#xD;
               -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
          2. Men with reproductive potential who do not agree to use an accepted and effective&#xD;
             method of contraception during the study treatment period and for at least 3 months&#xD;
             after completion of the study treatment&#xD;
&#xD;
          3. History of other malignancies within 5 years prior to Day 1 except for tumors that in&#xD;
             the opinion of the investigators have a negligible risk for metastasis or death, such&#xD;
             as (but not exclusively) adequately controlled basal cell carcinoma, squamous cell&#xD;
             carcinoma of the skin, or early stage bladder cancer&#xD;
&#xD;
          4. Current, or recent (within 4 weeks of the first treatment of this study) cytotoxic&#xD;
             chemotherapy (eg, cisplatin, taxol) or experimental drug therapy, or planned&#xD;
             participation in an experimental drug study&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, significant vascular disease (eg, aortic aneurysm, aortic dissection),&#xD;
             symptomatic peripheral vascular disease, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          6. History of myocardial infarction or unstable angina within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          7. History of stroke or transient ischemic attack within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          8. The subject is known to be positive for the human immunodeficiency virus (HIV) and is&#xD;
             receiving antiretroviral therapies. Subjects known to be HIV positive who do not&#xD;
             require antiretroviral therapy will be eligible if they meet other entry criteria&#xD;
&#xD;
          9. Women who are pregnant or breastfeeding&#xD;
&#xD;
         10. Inability to comply with study and/or follow up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Knox</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Susan Knox</investigator_full_name>
    <investigator_title>Associate Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenious Acid</mesh_term>
    <mesh_term>Sodium Selenite</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02184533/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

